Italy changes marketing permission for blood-clotting medicine Proplex
Italy's medicines agency AIFA has published an official notice on 31 October 2026 in the Gazzetta Ufficiale, Italy's official gazette, about a change to the marketing authorization of Proplex. Marketing authorization is the official permission that lets a medicine be sold in a country. Proplex is a human medicine based on human prothrombin complex, a group of blood-clotting proteins. The excerpt does not say what the change is.
This summary was generated by AI; the official source prevails.
What does it mean?
Proplex is a medicine used by people, and Italy's medicines regulator has officially changed the permission under which it is sold. The notice does not describe what was changed, so the practical effect is unclear from this text.
Who is affected?
Patients who use Proplex and the company that holds its marketing permission.